메뉴 건너뛰기




Volumn 72, Issue 25, 2018, Pages 3370-3372

Prescriber Patterns of SGLT2i After Expansions of U.S. Food and Drug Administration Labeling

Author keywords

[No Author keywords available]

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; ERTUGLIFLOZIN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; ANTIDIABETIC AGENT;

EID: 85058874846     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2018.08.2202     Document Type: Letter
Times cited : (101)

References (5)
  • 1
    • 84944800184 scopus 로고    scopus 로고
    • Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes
    • Wanner, C., Inzucchi, S.E., Lachin, J.M., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
    • (2015) N Engl J Med , vol.373 , pp. 2117-2128
    • Wanner, C.1    Inzucchi, S.E.2    Lachin, J.M.3
  • 2
    • 85034766786 scopus 로고    scopus 로고
    • Canagliflozin and cardiovascular and renal events in type 2 diabetes
    • Neal, B., Perkovic, V., Mahaffey, K.W., et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377 (2017), 644–657.
    • (2017) N Engl J Med , vol.377 , pp. 644-657
    • Neal, B.1    Perkovic, V.2    Mahaffey, K.W.3
  • 3
    • 85031666948 scopus 로고    scopus 로고
    • Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: an NCDR Research to Practice project
    • Arnold, S.V., Inzucchi, S.E., Tang, F., et al. Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: an NCDR Research to Practice project. Eur J Prev Cardiol 24 (2017), 1637–1645.
    • (2017) Eur J Prev Cardiol , vol.24 , pp. 1637-1645
    • Arnold, S.V.1    Inzucchi, S.E.2    Tang, F.3
  • 4
    • 85019611136 scopus 로고    scopus 로고
    • Novel diabetes drugs and the cardiovascular specialist
    • Sattar, N., Petrie, M.C., Zinman, B., et al. Novel diabetes drugs and the cardiovascular specialist. J Am Coll Cardiol 69 (2017), 2646–2656.
    • (2017) J Am Coll Cardiol , vol.69 , pp. 2646-2656
    • Sattar, N.1    Petrie, M.C.2    Zinman, B.3
  • 5
    • 84862556665 scopus 로고    scopus 로고
    • FDA Drug Safety Communication
    • Available at: Accessed on July 11, 2018
    • Food and Drug Administration. FDA Drug Safety Communication. Available at: https://www.fda.gov/Drugs/DrugSafety/ucm500965.htm Accessed on July 11, 2018.


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.